NCT05541757

Rivaroxaban - Percutaneous Coronary Intervention

In-Vitro Evaluation of Anticoagulant Therapy Management When Urgent Percutaneous Coronary Intervention is Required in Rivaroxaban-Treated Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 30 (actual)
• Sponsor: Bursa Postgraduate Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 74 Years
• Healthy volunteers: —

Summary

We investigated in-vitro the management of intraprocedural anticoagulation in patients requiring immediate percutaneous coronary intervention(PCI) while using regular direct oral anticoagulants(DOACs). Twenty-five patients taking 20mg of rivaroxaban once daily comprised the study group, while five healthy volunteers included the control group. In study group, a beginning(24-hours after the last rivaroxaban dose) examination was performed. Then, the effects of basal and four different anticoagulant doses(50IU/kg unfractionated heparin(UFH), 100IU/kg UFH, 0.5mg/kg enoxaparin, and 1mg/kg enoxaparin) on coagulation parameters were investigated at the 4th and 12th hours following rivaroxaban intake. Anticoagulant activity was assessed mainly by anti-factor Xa(anti-Xa) levels.

Conditions

• Coronary Artery Disease
• Atrial Fibrillation

Interventions

Type	Name	Description
DRUG	In vitro heparin	In vitro heparin and in vitro LMWH

Timeline

• Start date: 2021-01-01
• Primary completion: 2022-01-01
• Completion: 2022-03-01
• First posted: 2022-09-15
• Last updated: 2022-09-15

Locations

1 site across 1 country: Turkey (Türkiye)

Regulatory

• FDA-regulated drug study